Jazz Pharmaceuticals acquires Chimerix (CMRX) for $935M, adding ONC201, a promising brain cancer drug. Find out why I believe ...

Jazz Pharmaceuticals will acquire biotech firm Chimerix for about $935 million in cash to gain access to its lead drug ...

Jazz Pharmaceuticals has announced a definitive agreement to acquire Chimerix, a US-based biotech firm, for approximately ...

Chimerix is currently awaiting an FDA decision on accelerated approval of a drug it’s developing for a type of glioma.

Jazz Pharmaceuticals has drummed up a deal in double time, agreeing to buy Chimerix for $935 million just days after its CEO ...

Jazz Pharmaceuticals said Wednesday it would spend nearly $1 billion to buy Chimerix and its experimental pill for a ...

Jazz Pharmaceuticals (JAZZ) and Chimerix (CMRX) announced the companies have entered into a definitive agreement for Jazz to acquire Chimerix ...

Chimerix’s lead clinical pipeline candidate is dordaviprone, a first-in-class small molecule treatment designed to selectively target the mitochondrial protease ClpP and dopamine receptor D2 (DRD2).

Dordaviprone addresses a significant unmet patient need for patients with rare, high-grade brain tumors--Transaction to add near-term commercial ...

The decision to acquire Chimerix comes just a few months after Jazz claimed FDA approval for Ziihera (zanidatamab), its ...

Jazz Pharmaceuticals (NASDAQ:JAZZ) has agreed to acquire the cancer drug developer Chimerix (CMRX) for $8.55 per share in cash, indicating a total transaction value of roughly $935M, the companies ...

The acquisition is expected to enhance Jazz's oncology portfolio by adding dordaviprone, a novel small molecule therapy in ...